A Novel Folic Acid Linked Drug Has Shown to Attenuate Inflammation and Disease Activity in Animal Model of Multiple Sclerosis
01.02.2021
Recently published research has indicated that folate receptor targeting therapy constrains inflammation in inflammatory demyelinating central nervous system lesions and may inhibit progression of the disease in animal model of multiple sclerosis (MS). This research has been conducted in co-operation with Turku PET Centre, Purdue University and Endocyte Inc (now part of Novartis Institutes for BioMedical Research, NIBR).